

TABLE 103e-5 MOLECULARLY TARGETED AGENTS (CONTINUED)

Drug	Target	Adverse Events	Notes
Multikinase inhibitors			
Sorafenib	Renal cell, hepatocellular, differentiated thyroid carcinoma	Diarrhea Hand-foot syndrome Other rash Hypertension CHF	Targets c-raf, VEGFR
Pazopanib	Renal cell carcinoma, soft tissue sarcoma	Fatigue Diarrhea/GI Hypertension Thromboses QTc	Target VEGFR, c-kit, PDGFR
Regorafenib	Second-line colorectal cancer; GI stromal tumor	Hypertension Hand-foot syndrome Thromboses Perforations	VEGFR/TIE2
Sunitinib	Renal cell carcinoma, pancreatic neuroendocrine tumor, GI stromal tumor	Fatigue Diarrhea Neutropenia	Target VEGFR
Vandetanib	Medullary thyroid cancer	Diarrhea Rash Hypertension Prolonged QTc Thromboses	Target VEGFR, ret, EGFR
Cabozantinib	Medullary thyroid cancer	Hypertension Wound healing Fistulas Osteonecrosis Proteinuria	Target VEGFR, c-met
Axitinib	Renal cell carcinoma, second line	Diarrhea/other GI Fatigue Hand-foot syndrome	Target VEGFR, PDGFR, c-kit
Proteasome Inhibitors			
Bortezomib	Multiple myeloma, mantle cell lymphoma	Neuropathy Thrombocytopenia GI	
Carfilzomib	Multiple myeloma, second line	Infusion reaction CHF Thrombocytopenia Pulmonary Tumor lysis	
Histone Deacetylase Inhibitors			
Vorinostat	Cutaneous T cell lymphoma, second line	Fatigue Diarrhea Thrombocytopenia Embolism	
Romidepsin	Cutaneous T cell lymphoma, second line	Nausea Vomiting Cytopenias Cardiac conduction	
mTOR Inhibitors			
Temsirolimus	Renal cell carcinoma, second line or poor prognosis	Stomatitis Thrombocytopenia Nausea Anorexia, fatigue Metabolic (glucose, lipid)	

(Continued)